Depot injections have been successfully introduced in certain markets and have illustrated the benefits of longer acting formulations. In 2003 the first atypical depot (2 week IM injection) was introduced to the schizophrenia market. The product showed very quickly the pharmacoeconomic benefits of a longer acting formulation by improving patient adherence and it quickly achieved blockbuster status. Two new atypical depot products were also approved by the FDA in 2009. In spite the success of these products, they all display certain limitations including:

  • Technical limit of depot technologies to provide consistent blood levels for more than 2-4 weeks.
  • Safety issues since the drug cannot be withdraw if needed .
  • Poor pharmacokinetic profile resulting in side effects at high plasma levels.

Our technologies overcome these barriers by extending the release to several months while maintaning zero order release pharmacokinetics. Furthermore, Delpor’s device allows for removal of the medication if needed; our system can be easily removed by any emergency room physician.

Comments are closed.